- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07663604
Assessment of Pain Experience in Fibromyalgia
17. juni 2026 oppdatert av: Zülal TATAR
Assessment of Pain Experience in Fibromyalgia Using Abstract Animations and Graphic Body Maps, and Determinants of Pain Quality
The aim of this study is to assess pain in individuals with fibromyalgia using abstract animations and graphical body maps, and to investigate the determinants of pain quality.
Studieoversikt
Status
Påmelding etter invitasjon
Forhold
Studietype
Observasjonsmessig
Registrering (Antatt)
70
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Şirnak
-
Denizli, Şirnak, Tyrkia (Türkiye)
- Pamukkale University
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Prøvetakingsmetode
Sannsynlighetsprøve
Studiepopulasjon
The study will be conducted on individuals followed by the Rheumatology Department of Pamukkale University Faculty of Medicine and diagnosed with Fibromyalgia according to the 2016 ACR Fibromyalgia Syndrome diagnostic criteria.
Beskrivelse
Inclusion Criteria:
- Being 18 years of age or older
- Being female
- Having a diagnosis of fibromyalgia syndrome according to the American Rheumatology Association Criteria
- Not receiving active physiotherapy and rehabilitation treatment
- Volunteering to participate in the study.
Exclusion Criteria:
- Having a serious pathology or disease that could compromise the assessment process or affect clinical decision-making (metastasis, cancer, untreated or unhealed fractures, central nervous system disease or history of diabetes, pain outside the musculoskeletal system)
- Having severe mental and psychological disorders
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Painimation Mobile App
Tidsramme: At baseline (Day 1)
|
An electronic pain assessment tool designed to measure the location, nature, and intensity of pain using "pain animations and graphical images."
Patients use a colorable body image to indicate the areas affected by pain.
They then select from eight animations that represent their pain experiences.
The size, speed, and intensity of these animations can be adjusted to accurately represent pain severity.
Painimation animations are derived from the McGill Pain Questionnaire Short Form.
They were developed through a human-centered design process involving patients with acute and chronic pain, clinicians, researchers, and design students.
The animations correspond to the following pain qualities: "pounding," "shooting," "throbbing," "tingling," "cramping," "burning," "stabbing," and "electrifying."
The area of the body affected by pain will be calculated based on the proportion of selected pixels.
|
At baseline (Day 1)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
PainDetect Questionnaire
Tidsramme: At baseline (Day 1)
|
The PainDetect Questionnaire is a simple, self-administered, and convenient screening questionnaire that allows for the identification of neuropathic pain components in patients with chronic pain.
It consists of four main sections.
The total score is calculated by summing the scores from the last three sections and ranges from -1 to 38.
Scores of 12 and below indicate that the neuropathic pain component is unlikely, while scores of 19 and above indicate a high probability of the neuropathic pain component being present.
Scores between 12 and 19 are considered inconclusive.
|
At baseline (Day 1)
|
|
Central Sensitization Scale
Tidsramme: At baseline (Day 1)
|
The Central Sensitization Scale consists of two sections.
Section A comprises 25 items that assess symptoms related to physical and emotional health commonly seen in disorders associated with central sensitization.
Each item is scored on a 5-point Likert scale ranging from (0) "never" to (4) "always," with a total score of 100.
Higher scores indicate a higher level of symptom presence.
Section B includes 7 diagnoses assessed within the scope of central sensitization syndrome (tension-type headache or migraine, fibromyalgia, irritable bowel syndrome, restless legs syndrome, temporomandibular joint disorder, chronic fatigue syndrome, and multiple chemical sensitivities) and three additional diagnoses reported to be associated with central sensitization (depression, anxiety or panic attacks, and neck injury).
Participants are asked the following question: "Have you been diagnosed by a doctor with any of the following conditions?" and the year of diagnosis is indicated.
|
At baseline (Day 1)
|
|
Pain Catastrophizing Scale
Tidsramme: At baseline (Day 1)
|
The Pain Catastrophizing Scale is a scale used to assess the psychological aspects of pain-related symptoms in three dimensions: rumination, helplessness, and amplification.
The scale includes 13 items related to specific emotions and thoughts defined as negative associations.
Five of these items relate to rumination, six to helplessness, and two to amplification.
Patients are asked how frequently they recall each thought in these items.
Each item is scored between 0-4, and the total score is calculated between 0-52.
|
At baseline (Day 1)
|
|
Brief Pain Inventory
Tidsramme: At baseline (Day 1)
|
The Brief Pain Inventory is a short, easy-to-administer assessment method that can be used to evaluate pain.
It consists of two sections: pain intensity and impairment caused by pain.
It has 4 items related to pain intensity and 7 items related to impairment caused by pain.
Each item is rated on a scale of 0 to 10.
The total score for both sections is calculated by summing the scores given to each item and dividing the sum by the number of questions, and ranges from 0 to 10. Higher scores indicate more pain and greater impairment caused by pain.
|
At baseline (Day 1)
|
|
Fatigue Severity Scale
Tidsramme: At baseline (Day 1)
|
Published by Krupp in 1989, the FSS consists of nine items.
For each item, the patient is asked to choose a number between 1 and 7 indicating how much they agree with the statement; 1 means strongly disagree, and 7 means strongly agree.
Generally, scores of 4 and above indicate severe fatigue.
|
At baseline (Day 1)
|
|
The Short Form-12 Health Questionnaire
Tidsramme: At baseline (Day 1)
|
A summary version of the Short Form-36 Health Questionnaire, the SF-12 can also be divided into physical and mental sections and consists of a total of 12 questions.
The physical component of the scale is scored between 24 and 56 points, while the mental component is scored between 19 and 60 points.
Higher scores on the scale indicate a higher quality of life.
|
At baseline (Day 1)
|
|
Hospital Anxiety and Depression Scale
Tidsramme: At baseline (Day 1)
|
The Hospital Anxiety and Depression Scale is a 14-item, two-factor scale that assesses patients' anxiety and depression levels.
Seven of these items assess anxiety, and the other seven assess depression.
Each item is scored on a four-point scale.
The total score for anxiety and depression ranges from 0 to 21. Scores between 0 and 7 indicate a normal emotional state.
Scores above 7 on either the anxiety or depression subscales have been reported to indicate the presence of anxiety and depressive disorders.
|
At baseline (Day 1)
|
|
Revised Fibromyalgia Impact Questionnaire
Tidsramme: At baseline (Day 1)
|
The Revised Fibromyalgia Impact Questionnaire is a questionnaire evaluating limitations and functional disability in patients with fibromyalgia.
It consists of 21 questions divided into three sections: function, general, and symptoms.
All questions are rated on a numerical scale from 0 to 10.
A score of 70 or higher indicates severe disability in this patient group.
Higher scores indicate greater fibromyalgia-related disability.
|
At baseline (Day 1)
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
3. februar 2026
Primær fullføring (Antatt)
3. april 2027
Studiet fullført (Antatt)
24. juni 2027
Datoer for studieregistrering
Først innsendt
17. juni 2026
Først innsendt som oppfylte QC-kriteriene
17. juni 2026
Først lagt ut (Faktiske)
23. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
23. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
17. juni 2026
Sist bekreftet
1. juni 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Painanimation
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .